NDAORALTABLET
Approved
Sep 2015
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
1
Data completeness
5/8 — Partial
VARUBI (rolapitant) by TerSera Therapeutics. Approved for postoperative nausea and vomiting. First approved in 2015.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VARUBI (rolapitant) is an oral neurokinin-1 (NK1) receptor antagonist approved in 2015 for the prevention of postoperative nausea and vomiting (PONV). It works by blocking NK1 receptors in the chemoreceptor trigger zone and gastrointestinal tract, inhibiting the cascade of neuronal events that trigger emesis.
$0.498MPart D
Peak3.4 years to LOEAt peak lifecycle with modest Part D uptake (474 claims in 2023), the brand is mature with limited growth runway; team size likely stable and focused on retention rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (1)
Clinical Trials (1)
A Randomized Controlled Study of Rolapitant for the Prevention of Nausea and Vomiting Following Surgery (Study P04937AM1)(COMPLETED)
Started Oct 2007
619 enrolled
Postoperative Nausea and Vomiting
Why This Matters for Your Career
Worked on VARUBI at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.